erlotinib has been researched along with codeine in 2 studies
Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (codeine) | Trials (codeine) | Recent Studies (post-2010) (codeine) |
---|---|---|---|---|---|
221 | 0 | 180 | 4,815 | 730 | 952 |
Protein | Taxonomy | erlotinib (IC50) | codeine (IC50) |
---|---|---|---|
Delta-type opioid receptor | Mus musculus (house mouse) | 10 | |
Kappa-type opioid receptor | Mus musculus (house mouse) | 10 | |
Mu-type opioid receptor | Homo sapiens (human) | 0.105 | |
Mu-type opioid receptor | Mus musculus (house mouse) | 10 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dalvie, D; Loi, CM; Smith, DA | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for erlotinib and codeine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for erlotinib and codeine
Article | Year |
---|---|
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |